What disease does capmatinib treat?

Capmatinib is a drug used to treat non-small cell lung cancer (NSCLC). Its main application area is for METexon14 skipping mutationNSCLC patients, which is a rare but important subtype of lung cancer.

METexon14 skipping mutation is a lung cancer-specific genetic mutation that leads to abnormal activation of MET kinase, thereby promoting the growth and spread of tumors. Capmatinib's unique design and mechanism of action make it an effective targeted therapy specifically for patients in this subtype.

Capmatinibover-inhibits the MET protein kinase and blocks the abnormal activation of the MET pathway, thus interfering with the growth signaling of tumor cells. This precise targeted therapy can more effectively inhibit tumor development and improve patient response to treatment while reducing adverse effects on healthy normal cells.

Clinical trial data show that capmatinib has achieved significant efficacy in METExon14skipping mutantNSCLC patients. It improves objective response rates, slows tumor growth and extends patient survival. Therefore, capmatinib has been approved for the treatment of patients with this specific subtype of NSCLC, providing a promising treatment option for this patient population.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.